Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)

MCC-21917: Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer (clinicaltrials.gov)

P2, N=8, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=36 --> 8

6 days ago

Enrollment closed • Enrollment change

HER-2 (Human epidermal growth factor receptor 2)

HER-2 overexpression • HER-2 amplification

Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • Nerlynx (neratinib) • oxaliplatin • leucovorin calcium

HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies. (PubMed, Int J Mol Sci)

A cross-tumor perspective contrasts GC/GEJ testing and biology with the breast cancer paradigm and summarizes the importance of HER2-low expression in non-gastric malignancies. Finally, we discuss the therapeutic strategies in HER2-low GC/GEJ and highlight key safety and monitoring considerations for HER2-directed ADCs.

6 days ago

Review • Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 underexpression • HER-2 positive + HER-2 overexpression

Enhertu (fam-trastuzumab deruxtecan-nxki) • Aidixi (disitamab vedotin)

IMC001 EpCAM: Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors. (clinicaltrials.gov)

P1/2, N=30, Enrolling by invitation, Suzhou Immunofoco Biotechnology Co., Ltd

6 days ago

New P1/2 trial

IMC001 • danburstotug (IMC-001)

Architectural Refuges: Mapping Spatial Heterogeneity and Niche-Mediated Drug Resistance in Gastric and Esophageal Adenocarcinomas. (PubMed, Cancers (Basel))

We delineate three critical resistance domains common to upper gastrointestinal adenocarcinomas: (1) The "Excluded" Niche, where specific cancer-associated fibroblast (CAF) subpopulations (iCAFs vs. myCAFs) and stiffened extracellular matrix create hypovascular zones that limit drug delivery; (2) the "Immune-Tolerant" Niche, characterized by the spatial exclusion of CD8+ T cells and the recruitment of suppressive myeloid populations via the MIF/CD74 and USP14 axes; and (3) the "Metabolic" Niche, where mitochondrial heterogeneity and lipid metabolic symbiosis establish nutrient-deprived niches that select for stem-like, dormant states. By mapping these conserved spatial determinants from primary GEJ tumors to peritoneal and distant metastases, we argue that overcoming resistance requires an advancement: moving beyond targeting individual mutations to dismantling the multicellular architecture that sustains malignancy.

6 days ago

Review • Journal

CD8 (cluster of differentiation 8) • CD74 (CD74 Molecule) • USP14 (Ubiquitin Specific Peptidase 14)

AK117-204: A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors (clinicaltrials.gov)

P1/2, N=128, Completed, Akeso | Trial completion date: Mar 2024 --> May 2026 | Trial primary completion date: Mar 2023 --> May 2026 | Recruiting --> Completed

7 days ago

Trial completion • Trial completion date • Trial primary completion date

cisplatin • paclitaxel • docetaxel • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • Kaitanni (cadonilimab) • ligufalimab (AK117)

Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. (PubMed, Int J Cancer)

The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5-fluororuracil, leucovorin and irinotecan) in this setting...Elevated PlGF-particularly its early increase during RAM-based therapy-was associated with shortened survival and may represent a dynamic marker of unfavorable prognosis in advanced gastric/GEJ adenocarcinoma. Given the exploratory nature of this analysis, these findings should be considered hypothesis-generating and require validation in independent biomarker-driven studies.

8 days ago

P2 data • Journal

CA9 (Carbonic anhydrase 9)

paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)

P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026

9 days ago

Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden

HER-2 (Human epidermal growth factor receptor 2)

HER-2 overexpression

Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)

How to Define the Gastroesophageal Junction. (PubMed, Dig Endosc)

Furthermore, we will briefly discuss endoscopic treatment, chemotherapy, and surgical treatment for GEJ cancer. Looking ahead, the reclassification of GEJ cancers using the Kyoto international consensus, coupled with comprehensive molecular analyses of tumors, promises to yield valuable insights.

9 days ago

Review • Journal

CDX2 (Caudal Type Homeobox 2)

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov)

P=N/A, N=96, Recruiting, Tang-Du Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

9 days ago

Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

PD-L1 expression

capecitabine • oxaliplatin • Hetronifly (serplulimab)

Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer (clinicaltrials.gov)

P=N/A, N=52, Recruiting, Qilu Hospital of Shandong University

9 days ago

New trial • HEOR